Management of Autoimmune Skin Diseases

Management of Autoimmune Skin Diseases

Management of Autoimmune Skin Diseases

On this page

Principles & Corticosteroids - First-Line Firefight

  • Management Goals:
    • Induce remission (rapid control).
    • Maintain remission, prevent flares.
    • Minimize treatment side effects.
    • Enhance Quality of Life (QoL).
  • Corticosteroids (CS): First-line; potent anti-inflammatory, immunosuppressive.
    • Topical CS:
      • Potency (mild to superpotent) based on site & severity.
      • E.g., Hydrocortisone (face), Clobetasol (palms/soles).
      • SE: Atrophy, striae, telangiectasia, tachyphylaxis. Topical Corticosteroid Potency Classes
    • Systemic CS: For severe/widespread disease.
      • Oral Prednisolone: 1-2 mg/kg/day initially, then slow taper.
      • IV Pulse Therapy (e.g., Dexamethasone-Cyclophosphamide Pulse - DCP) for aggressive forms like Pemphigus.
      • SE: Cushing's, osteoporosis, ↑infection risk, HPA axis suppression, PUD.
      • Monitor: BP, glucose, electrolytes.
    • Intralesional CS (ILCS): Localized lesions (e.g., DLE, keloids). Triamcinolone acetonide (2.5-10 mg/mL).

⭐ Prednisolone 1-1.5 mg/kg/day is the initial standard for Pemphigus Vulgaris to achieve rapid blister control.

Steroid-Sparing Agents - Backup Brigade Buddies

Use: ↓ steroids, maintain remission. Monitor labs per agent.

  • Azathioprine (AZA)
    • Purine analogue. 1-3 mg/kg/d. Onset: 6-12w.
    • SE: Myelosuppression (check TPMT), hepatotoxic, pancreatitis. ⭐ > TPMT testing vital before Azathioprine: prevents severe myelosuppression in at-risk patients.
  • Methotrexate (MTX)
    • Folate antagonist. 7.5-25 mg/wk (+folic acid). Onset: 4-8w.
    • SE: Myelosuppression, hepatotoxic, pneumonitis, teratogen.
  • Mycophenolate Mofetil (MMF)
    • IMPDH inhibitor. 1-2 g/d. Onset: 4-8w.
    • SE: GI upset, myelosuppression.
  • Cyclosporine (CsA)
    • Calcineurin inhibitor. 2.5-5 mg/kg/d. Onset: 2-4w (rapid).
    • SE: Nephrotoxic, HTN, neurotoxic.
  • Cyclophosphamide (CYC) (Severe cases)
    • Alkylating agent.
    • SE: Myelosuppression, hemorrhagic cystitis, infertility, malignancy.
  • Dapsone
    • Anti-inflammatory. 50-200 mg/d.
    • SE: Hemolysis (check G6PD), methemoglobinemia.

Biologics & IVIG - Precision Power-Ups

  • Biologics: Target refractory autoimmune skin diseases.
    • Mechanism: Target specific cytokines or immune cells.
    • Key Examples (Disease):
      • TNF-α inhibitors (Infliximab): Psoriasis, HS.
      • IL-17 inhibitors (Secukinumab): Psoriasis.
      • IL-23 inhibitors (Guselkumab): Psoriasis.
      • Rituximab (anti-CD20): Pemphigus Vulgaris (PV), Bullous Pemphigoid (BP).
      • Omalizumab (anti-IgE): Chronic Spontaneous Urticaria (CSU).
    • Pre-therapy screening: TB, Hepatitis B/C.
  • IVIG (Intravenous Immunoglobulin):
    • Mechanism: Broad immunomodulatory effects.
    • Uses: Severe PV, BP, Dermatomyositis.
    • Dose: 0.4-2 g/kg per cycle.
    • Adverse Effects: Headache, renal toxicity (sucrose preps), thrombosis. Ustekinumab Approval Timeline for Psoriasis

⭐ Rituximab significantly reduces steroid dependence in Pemphigus Vulgaris.

Adjunctive Care - Holistic Healing Hints

  • Sun Protection: Crucial for photosensitive conditions (e.g., SLE, dermatomyositis).
    • Broad-spectrum sunscreen (SPF >30, PA+++).
    • Protective clothing, seek shade.
  • Gentle Skincare:
    • Mild, non-irritant cleansers.
    • Regular use of emollients/moisturizers to maintain skin barrier.
  • Diet & Lifestyle:
    • Balanced nutrition; address deficiencies (e.g., Vitamin D).
    • Smoking cessation (worsens many conditions, e.g., DLE, psoriasis).
    • Stress reduction techniques (yoga, meditation).
  • Psychological Support: Address anxiety/depression common with chronic skin disease.
  • Physiotherapy: For joint involvement or contractures (e.g., scleroderma).
  • Vaccinations: Update as per guidelines, especially for immunosuppressed patients (avoid live vaccines during active immunosuppression).

⭐ Vitamin D supplementation is often recommended in autoimmune diseases due to its immunomodulatory effects and high prevalence of deficiency, particularly in patients with limited sun exposure or on corticosteroids. Monitor levels; aim for >30 ng/mL.

  • Regular Monitoring: For disease activity, treatment side effects, and associated comorbidities (e.g., thyroid disease in vitiligo).

High‑Yield Points - ⚡ Biggest Takeaways

  • Topical and systemic corticosteroids are primary for acute control.
  • Immunosuppressants (azathioprine, methotrexate, MMF) act as crucial steroid-sparing agents.
  • Rituximab shows high efficacy in refractory Pemphigus Vulgaris.
  • Bullous Pemphigoid typically responds to potent topical steroids or moderate systemic doses.
  • Dapsone is the mainstay treatment for Dermatitis Herpetiformis.
  • Hydroxychloroquine is key for managing Cutaneous Lupus Erythematosus.
  • Vigilant monitoring for adverse effects of immunosuppressive therapy is essential.

Practice Questions: Management of Autoimmune Skin Diseases

Test your understanding with these related questions

What is the primary condition for which calcitriol is used as a treatment?

1 of 5

Flashcards: Management of Autoimmune Skin Diseases

1/10

_____ is an autoimmune inactivation of desmosomes between keratinocytes

TAP TO REVEAL ANSWER

_____ is an autoimmune inactivation of desmosomes between keratinocytes

Pemphigus vulgaris

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial